10x Genomics, Inc. Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. 10x Genomics, Inc. is a life sciences technology company providing integrated solutions, including Chromium and Spatial instruments, consumables, and software, to analyze biological systems. The company is headquartered in Pleasanton, California, and operates globally.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $151.7 million | $153.6 million | $445.8 million | $434.7 million |
| Gross Profit | $106.4 million | $95.5 million | $303.5 million | $293.5 million |
| Gross Margin | 70% | 62% | 68% | 68% |
| Net Loss | $(35.8) million | $(93.0) million | $(133.6) million | $(206.1) million |
| Operating Cash Flow (9M) | $13.4 million (2024) vs $(41.0) million (2023) | |||
| Cash & Equivalents | $398.2 million (as of Sept 30, 2024) | |||
| Accumulated Deficit | $1.4 billion (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue decreased slightly by 1% in Q3 2024. This was driven by a 45% decline in instrument revenue (down $15.9M) due to lower sales volume of Chromium and Spatial instruments. Conversely, consumables revenue increased 10% (up $11.8M), primarily driven by a 111% surge in Spatial consumables sales.
- Improved Profitability: Gross margin expanded to 70% in Q3 2024 from 62% in the prior year, attributed to a favorable change in product mix. Net loss narrowed significantly to $35.8 million from $93.0 million year-over-year.
- Expense Reduction: Total operating expenses decreased 22% in Q3 2024 compared to Q3 2023. This reduction was largely due to the absence of a $41.4 million in-process research and development charge recorded in the prior year, alongside lower personnel and stock-based compensation expenses.
- Cash Flow Turnaround: Operating cash flow turned positive for the nine months ended September 30, 2024 ($13.4 million), compared to a negative $41.0 million in the same period in 2023.
Outlook, Risks, and Contingencies
- Liquidity: Management believes existing cash and cash equivalents ($398.2 million) are sufficient to meet anticipated needs for at least the next 12 months. Capital expenditures are expected to range between $15 million and $20 million over the next year.
- Legal Proceedings (NanoString): A jury awarded 10x Genomics over $31 million in damages against NanoString for patent infringement. However, NanoString filed for Chapter 11 bankruptcy in February 2024, and its assets were acquired by Bruker Corporation. Due to collection uncertainties, 10x Genomics has not recorded a receivable for this award. Post-trial motions are pending.
- Legal Proceedings (Vizgen & Parse): Ongoing patent litigation with Vizgen and Parse Biosciences involves mutual infringement claims and counterclaims regarding antitrust and unfair competition. Trials are scheduled for 2025.
- Legal Proceedings (Curio): 10x Genomics obtained a preliminary injunction in the Unified Patent Court (UPC) against Curio Bioscience in Germany, France, and Sweden. A main request trial is pending.
- Forward-Looking Risks: The company expects to continue incurring operating losses in the near term. Risks include the outcome of ongoing litigation, the ability to capture market opportunities, and potential changes in interest rates or foreign currency exchange rates.
Investor Verification Checklist
- Verify the collectability of the $31 million jury award against NanoString given the bankruptcy and asset acquisition by Bruker.
- Monitor the trajectory of Spatial consumables revenue growth to determine if it can offset the decline in instrument sales.
- Review the status of the $2.1 million impairment charge related to discontinued software projects and potential future write-downs.
- Assess the impact of ongoing litigation costs and potential damages from counterclaims filed by Vizgen and Parse.
- Confirm the sustainability of the 70% gross margin as product mix fluctuates and royalty obligations vary.